BidaskClub upgraded shares of NxStage Medical (NASDAQ:NXTM) from a hold rating to a buy rating in a report released on Tuesday morning.
Several other research analysts have also recently weighed in on the stock. ValuEngine upgraded shares of NxStage Medical from a hold rating to a buy rating in a report on Saturday, June 2nd. Zacks Investment Research cut shares of NxStage Medical from a hold rating to a strong sell rating in a report on Tuesday, May 15th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $30.50.
NxStage Medical stock opened at $27.90 on Tuesday. NxStage Medical has a fifty-two week low of $22.70 and a fifty-two week high of $29.93.
NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings results on Thursday, May 10th. The medical device company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.04). NxStage Medical had a negative return on equity of 6.83% and a negative net margin of 3.65%. The firm had revenue of $107.30 million for the quarter, compared to analysts’ expectations of $106.95 million. equities research analysts forecast that NxStage Medical will post -0.01 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. raised its position in NxStage Medical by 8.9% in the first quarter. BlackRock Inc. now owns 4,787,684 shares of the medical device company’s stock worth $119,023,000 after acquiring an additional 390,594 shares during the period. Flossbach Von Storch AG bought a new stake in NxStage Medical in the first quarter worth about $74,411,000. Pennant Capital Management LLC raised its position in NxStage Medical by 8.3% in the fourth quarter. Pennant Capital Management LLC now owns 1,756,354 shares of the medical device company’s stock worth $42,556,000 after acquiring an additional 134,288 shares during the period. Water Island Capital LLC raised its position in NxStage Medical by 47.3% in the first quarter. Water Island Capital LLC now owns 1,184,707 shares of the medical device company’s stock worth $29,452,000 after acquiring an additional 380,561 shares during the period. Finally, State of Wisconsin Investment Board raised its position in NxStage Medical by 4.5% in the first quarter. State of Wisconsin Investment Board now owns 1,103,947 shares of the medical device company’s stock worth $27,444,000 after acquiring an additional 47,500 shares during the period. 82.10% of the stock is currently owned by institutional investors and hedge funds.
NxStage Medical Company Profile
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.